GLP-1 Agonists Show Strong Efficacy Against MASH and Liver Fibrosis
Background
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, is a severe form of fatty liver disease that can progress to cirrhosis and liver failure. A critical prognostic factor in MASH is the presence and progression of liver fibrosis, which currently lacks highly effective, approved pharmacological treatments. This systematic review and meta-analysis addresses the urgent need to evaluate the efficacy and safety of GLP-1 receptor agonists (GLP-1 RAs) as a therapeutic option for MASH patients with existing liver fibrosis.
Results
The meta-analysis revealed a significant and consistent benefit of GLP-1 RAs in MASH patients with fibrosis across the included studies. GLP-1 receptor agonists achieved MASH resolution without worsening of fibrosis in a remarkable 48% of treated patients, demonstrating a pooled odds ratio of 3.25 (95% CI: 2.88-3.67, p<0.001) compared to only 15% in placebo or standard care groups. Specifically, 35% of patients receiving GLP-1 RAs experienced at least a one-stage improvement in liver fibrosis, which was significantly higher than the 12% observed in control groups (p<0.001). Furthermore, the analysis indicated a 2.1-fold reduction in the risk of progression to cirrhosis over a 2-year follow-up period in the GLP-1 RA cohorts. The safety profile was generally favorable, with gastrointestinal adverse events (e.g., nausea, diarrhea) being the most common, reported in 28% of GLP-1 RA patients versus 10% in controls, consistent with known class effects.
Why It Matters
This robust systematic review and meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in achieving MASH resolution and improving liver fibrosis, addressing a major unmet medical need in a complex patient population. The consistent positive findings across numerous trials underscore a powerful therapeutic potential. These results strongly support the potential for GLP-1 RAs to become a cornerstone therapy for MASH with fibrosis, offering a promising strategy to prevent disease progression to cirrhosis and liver failure. Further large-scale Phase III clinical trials are warranted to confirm these findings and establish long-term safety and efficacy profiles in diverse patient populations, potentially leading to regulatory approval for this indication.